BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 24045554)

  • 1. Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance.
    Lambein K; Van Bockstal M; Vandemaele L; Geenen S; Rottiers I; Nuyts A; Matthys B; Praet M; Denys H; Libbrecht L
    Am J Clin Pathol; 2013 Oct; 140(4):561-6. PubMed ID: 24045554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
    Clay MR; Iberri DJ; Bangs CD; Cherry A; Jensen KC
    Am J Surg Pathol; 2013 Jan; 37(1):120-7. PubMed ID: 23108020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.
    Yosepovich A; Avivi C; Bar J; Polak-Charcon S; Mardoukh C; Barshack I
    Isr Med Assoc J; 2010 Jun; 12(6):353-6. PubMed ID: 20928989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual HER2 gene protein assay: focused study of breast cancers with 2+ immunohistochemical expression.
    Li Z; Dabbs DJ; Cooper KL; Bhargava R
    Am J Clin Pathol; 2015 Mar; 143(3):451-8. PubMed ID: 25696805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression profiling of breast tumors based on human epidermal growth factor receptor 2 status defines migration-related genes.
    Cuadros M; Cano C; López FJ; López-Castro R; Concha A
    Pathobiology; 2013; 80(1):32-40. PubMed ID: 22832278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.
    Shah SS; Ketterling RP; Goetz MP; Ingle JN; Reynolds CA; Perez EA; Chen B
    Hum Pathol; 2010 Jan; 41(1):103-6. PubMed ID: 19762065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 testing of multifocal invasive breast carcinoma: how many blocks are enough?
    Bethune GC; Mullen JB; Chang MC
    Am J Clin Pathol; 2013 Oct; 140(4):588-92. PubMed ID: 24045558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 testing in breast cancer: NCCN Task Force report and recommendations.
    Carlson RW; Moench SJ; Hammond ME; Perez EA; Burstein HJ; Allred DC; Vogel CL; Goldstein LJ; Somlo G; Gradishar WJ; Hudis CA; Jahanzeb M; Stark A; Wolff AC; Press MF; Winer EP; Paik S; Ljung BM;
    J Natl Compr Canc Netw; 2006 Jul; 4 Suppl 3():S1-22; quiz S23-4. PubMed ID: 16813731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2-testing in 538 consecutive breast cancer cases using FISH and immunohistochemistry.
    Kovács A; Stenman G
    Pathol Res Pract; 2010 Jan; 206(1):39-42. PubMed ID: 19819642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
    Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
    Dressler LG; Berry DA; Broadwater G; Cowan D; Cox K; Griffin S; Miller A; Tse J; Novotny D; Persons DL; Barcos M; Henderson IC; Liu ET; Thor A; Budman D; Muss H; Norton L; Hayes DF
    J Clin Oncol; 2005 Jul; 23(19):4287-97. PubMed ID: 15994142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples.
    Arihiro K; Oda M; Ogawa K; Tominaga K; Kaneko Y; Shimizu T; Matsumoto S; Oda M; Kurita Y; Taira Y
    Jpn J Clin Oncol; 2013 Jan; 43(1):55-62. PubMed ID: 23225912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast.
    Lee AH; Key HP; Bell JA; Hodi Z; Ellis IO
    Histopathology; 2012 May; 60(6):880-4. PubMed ID: 22320892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
    Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center.
    Murthy SS; Sandhya DG; Ahmed F; Goud KI; Dayal M; Suseela K; Rajappa SJ
    Indian J Pathol Microbiol; 2011; 54(3):532-8. PubMed ID: 21934215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancers presenting luminal B subtype features show higher discordant human epidermal growth factor receptor 2 results between immunohistochemistry and fluorescence in situ hybridization.
    Park S; Park HS; Koo JS; Yang WI; Kim SI; Park BW
    Cancer; 2012 Feb; 118(4):914-23. PubMed ID: 21800290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Availability of fine needle aspirates for the assessment of HER2 gene amplification in invasive breast cancer patients].
    Lee JW; Noh WC; Kim MS; Kim HA; Chang YH; Hong YJ; Hong SI; Lee JK
    Korean J Lab Med; 2008 Oct; 28(5):392-9. PubMed ID: 18971621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry?
    Barrett C; Magee H; O'Toole D; Daly S; Jeffers M
    J Clin Pathol; 2007 Jun; 60(6):690-3. PubMed ID: 16822876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations.
    Lambein K; Praet M; Forsyth R; Van den Broecke R; Braems G; Matthys B; Cocquyt V; Denys H; Pauwels P; Libbrecht L
    J Clin Pathol; 2011 Mar; 64(3):200-7. PubMed ID: 21177747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
    Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
    Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.